PDUFA DEADLINE IS FOR REAL: CONGRESS WON'T EXTEND SESSION TO FINISH FDA WORK, FDA's SCHULTZ CAUTIONS; SENATE DEBATE BEGINS, CLOTURE OVERRIDES KENNEDY DELAY
The need to pass a bill to reauthorize the Prescription Drug User Fee Act will not keep Congress in session, FDA Deputy Commissioner for Policy William Schultz pointed out at a Sept. 3 Food & Drug Law Institute meeting in Washington, D.C.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth